Survodutide Improves Beta Cell Function and Insulin Sensitivity in T2D and Obesity
Trial shows survodutide improves insulin sensitivity and beta-cell function
Survodutide demonstrates significant improvements in beta-cell function and insulin sensitivity across both T2D and overweight populations.
A new medication called survodutide may improve how the body handles insulin and supports the cells that produce it for people with type 2 d…
Survodutide reduces mean body weight by 12.2% or 13.0% in adults with obesity
Trial shows survodutide helps adults lose weight over 76 weeks
This Phase 3 randomized controlled trial evaluated survodutide in 725 adults with a BMI of 30 or higher, or 27 or higher with obesity-relate…
A new trial shows that the weekly injection survodutide helps people with obesity lose significant weight compared to a placebo.
GLP-1 receptor agonists and tirzepatide provide cardiovascular benefits across multiple clinical scenarios
Incretin Drugs Show Heart Benefits Across Multiple Conditions
This state-of-the-art review synthesizes evidence regarding incretin analogues, specifically GLP-1 receptor agonists and tirzepatide. The re…
GLP-1 drugs and tirzepatide prove heart benefits in diabetes, obesity, heart failure, and more.